0000000000300192

AUTHOR

James H. Clark

0000-0002-5860-2480

showing 2 related works from this author

Advances in plant materials, food by-products, and algae conversion into biofuels: use of environmentally friendly technologies

2019

Green technologies have emerged as useful tools for the generation of clean fuels with the potential to minimize the effect of human activity on the environment. Currently, these fuels are mainly composed of hydrocarbons obtained from crude oil. Over the past two decades, biomass has gained significant attention as a renewable feedstock for more sustainable biofuel production and has been a great candidate to replace fossil fuels. The principal components of most of the available biomass are cellulose, hemi-cellulose, and lignin. Although the available green technologies for biofuel production are progressing rapidly, productivity and chemical yield from these techniques are still below the…

2310[SDV.BIO]Life Sciences [q-bio]/BiotechnologyBiomassContext (language use)Raw material010402 general chemistry7. Clean energy01 natural sciences12. Responsible consumption[SDV.IDA]Life Sciences [q-bio]/Food engineeringEnvironmental ChemistryComputingMilieux_MISCELLANEOUS010405 organic chemistrybusiness.industryFossil fuel2304[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologySustainable biofuelPollutionEnvironmentally friendly0104 chemical sciencesRenewable energy[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry Molecular Biology/Biomolecules [q-bio.BM]13. Climate actionBiofuelEnvironmental scienceBiochemical engineeringbusiness[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance

2022

Background & Aims Serum microRNA (miRNA) levels are known to change in non-alcoholic fatty liver disease (NAFLD) and may serve as useful biomarkers. This study aimed to profile miRNAs comprehensively at all NAFLD stages. Methods We profiled 2,083 serum miRNAs in a discovery cohort (183 cases with NAFLD representing the complete NAFLD spectrum and 10 population controls). miRNA libraries generated by HTG EdgeSeq were sequenced by Illumina NextSeq. Selected serum miRNAs were profiled in 372 additional cases with NAFLD and 15 population controls by quantitative reverse transcriptase PCR. Results Levels of 275 miRNAs differed between cases and population controls. Fewer differences were seen wi…

SCORING SYSTEMCPM counts per millionAUROC area under the receiver operating characteristicRC799-869AST aspartate aminotransferaseMicroRNA; Non-alcoholic fatty liver disease; Biomarker; SequencingTGF-β transforming growth factor-betaGastroenterologySTEATOHEPATITISLiver disease0302 clinical medicineFibrosismiRNA microRNAlogFC log2 fold changeFIBROSISImmunology and AllergySequencing0303 health scienceseducation.field_of_studyNAS NAFLD activity scoremedicine.diagnostic_testFatty liverGastroenterologyGTEx Genotype-Tissue ExpressionMicroRNADiseases of the digestive system. Gastroenterology3. Good healthReal-time polymerase chain reactionBiomarker MicroRNA Non-alcoholic fatty liver disease SequencingLiver biopsyACIDBiomarker (medicine)030211 gastroenterology & hepatologyLife Sciences & BiomedicineResearch ArticleEXPRESSIONmedicine.medical_specialtyNAFLD non-alcoholic fatty liver diseaseNASH non-alcoholic steatohepatitisPopulationGastroenterology and HepatologySAF steatosis–activity–fibrosisVALIDATIONER endoplasmic reticulum03 medical and health sciencescDNA complementary DNAInternal medicineALT alanine aminotransferaseGastroenterologiInternal MedicinemedicineNAFL non-alcoholic fatty liverALGORITHMFIB-4 fibrosis-4education030304 developmental biologyPCA principal component analysisScience & TechnologyGastroenterology & HepatologyHepatologybusiness.industryBiomarkerFC fold changemedicine.diseaseBiomarker; MicroRNA; Non-alcoholic fatty liver disease; Sequencingdigestive system diseasesFLIP fatty liver inhibition of progressionCt cycle thresholdSteatosisqPCR quantitative PCRbusinessNon-alcoholic fatty liver disease
researchProduct